Evidence map›Paper›PMID 30376092›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Lab Protocol Paper: Use of a High-throughput, Multiplex Reverse-transcription Quantitative Polymerase Chain Reaction Assay for Detection of Sabin Oral Polio Vaccine in Fecal Samples.

Christopher van Hoorebeke, ChunHong Huang, Sean Leary, Marisa Holubar, Jonathan Altamirano, Meira S Halpern, Marvin Sommer, Yvonne Maldonado

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. OPV Vaccination and Shedding Patterns in Mexican and US Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  2. Assessing the Risk of Vaccine-derived Outbreaks After Reintroduction of Oral Poliovirus Vaccine in Postcessation Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christopher van HoorebekeStanford University School of Medicine, California.
ChunHong HuangStanford University School of Medicine, California.
Sean LearyStanford University School of Medicine, California.
Marisa HolubarStanford University School of Medicine, California.
Jonathan AltamiranoStanford University School of Medicine, California.
Meira S HalpernStanford University School of Medicine, California.
Marvin SommerStanford University School of Medicine, California.
Yvonne MaldonadoStanford University School of Medicine, California.

Funding

Global Epidemiology of Infectious DiseasesT32AI052073 · NIAID · STANFORD UNIVERSITY · PI Angelle Desiree LaBeaud, Stephen Patrick Luby · 2003 to 2026
$4.2M
NIAID NIH HHS T32 AI052073
6 · The paper itself

Abstract

Background: Global polio eradication efforts rely in part on molecular methods of detecting polioviruses, both wild and vaccine strains, from human and environmental samples. Previous assays used for detection of Sabin oral polio vaccine (OPV) in fecal samples have been labor and time intensive and vary in their sensitivity and specificity. Methods: We developed a high-throughput, multiplex reverse-transcription quantitative polymerase chain reaction assay able to detect all 3 OPV strains in fecal samples. The assay used a KingFisher Duo Prime system for viral RNA isolation and extraction. Positive samples were retested and Sanger sequenced for verification of Sabin serotype identity. Results: The 95% lower limit of detection was determined to be 3 copies per reaction for Sabin 1 and 3 and 4 copies per reaction for Sabin 2, with no cross-reactivity between the 3 serotypes and their primers. A total of 554 samples (3.6%) were positive, with 304 positive samples (54.9%) containing >1 serotype. Of the positive samples, 476 (85.9%) contained enough RNA to be sequenced, and of these all sequences were Sabin serotypes. The previous assay we used could process 48 samples in a 10-hour period, whereas the new assay processed >100 samples in 6 hours. Conclusions: The new high-throughput, multiplex reverse-transcription quantitative polymerase chain reaction assay allowed for sensitive and specific detection of OPV serotypes while greatly decreasing sample handling and processing time. We were able to sequence 72.4% of the 210 positive samples in the cycle threshold range of 35-37.

Indexed as

Child, PreschoolCross ReactionsFecesHigh-Throughput Nucleotide SequencingHumansInfantLimit of DetectionMexicoMultiplex Polymerase Chain ReactionPoliomyelitisPoliovirusPoliovirus Vaccine, OralSensitivity and SpecificitySequence Analysis, DNASerogroupPoliovirus Vaccine, Oral

Identifiers

PMID30376092
PMCPMC6206103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.